PALI PALISADE BIO INC

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the being held February 6-8, 2025 in San Francisco, CA.

Details of the poster presentation are as follows:

Session: Poster and Exhibition Hall Reception

Poster Title: PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model

Session Dates and Times: February 7, 2025 from 5:00 PM to 6:30 PM PST

Presentation Location: Level 1 – Exhibition Hall – Moscone West

For more information about the congress, please visit .

About Palisade Bio 

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to .

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

908-824-0775



EN
29/01/2025

Underlying

PALIPALISADE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALISADE BIO INC

 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Presents Positive Preclinical Data Highlighting Potential...

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade B...

May 6, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Se...

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the being held May 13–15, 2025 in Boston, MA. Detai...

May 1, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/...

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108 No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed to date Screening for Phase 1b UC cohort ongoing; On track to report topline data in the first half of 2025 Carlsbad, CA, April 09, 2025 (GLOBE NEWSWIRE) -- P...

April 9, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Coho...

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious adverse events (SAEs) and no treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs seen to date On track to report topline data in first half of 2025 Carlsbad, CA, March 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Compa...

March 14, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poste...

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW Carlsbad, CA, March 12, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, a...

March 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch